Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.210
+0.040 (+3.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptimmune Ther ADR
< Previous
1
2
3
4
5
6
Next >
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
October 27, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 25, 2022
Gainers DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million.
Via
Benzinga
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
October 25, 2022
Via
Benzinga
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
October 25, 2022
Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –GSK to deliver data from the ongoing...
Via
Newsfile
Domino's Pizza To $385? Plus This Analyst Cuts Price Target On Adaptimmune Therapeutics By Around 79%
October 04, 2022
UBS cut the price target on Domino's Pizza, Inc. (NYSE: DPZ) from $430 to $385. Domino's shares rose 4% to $329.11 on Tuesday.
Via
Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
September 09, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 09, 2022
Via
Benzinga
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
September 09, 2022
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian,...
Via
Newsfile
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
August 25, 2022
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp....
Via
Newsfile
Adaptimmune Therapeutics: Q2 Earnings Insights
August 04, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Adaptimmune Reports Second-Quarter Financial Results and Business Update
August 04, 2022
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission...
Via
Newsfile
Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022
July 21, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 03, 2022
Via
Benzinga
Adaptimmune Therapeutics's Return On Capital Employed Insights
June 03, 2022
Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter.
Via
Benzinga
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
May 26, 2022
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) --...
Via
Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
May 16, 2022
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million.
Via
Benzinga
Adaptimmune Therapeutics: Q1 Earnings Insights
May 09, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
May 06, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET
May 04, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
March 16, 2022
According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 15, 2022
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
Adaptimmune Therapeutics: Q4 Earnings Insights
March 14, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Earnings Scheduled For March 14, 2022
March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (...
Via
Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
March 11, 2022
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement....
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
January 21, 2022
Gainers Mustang Bio (NASDAQ:MBIO) shares ...
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.